Home  |  Contact

UniProtKB/Swiss-Prot P26678: Variant p.Arg9His

Cardiac phospholamban
Gene: PLN
Variant information

Variant position:  9
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Arginine (R) to Histidine (H) at position 9 (R9H, p.Arg9His).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and polar (H)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Cardiomyopathy, dilated 1P (CMD1P) [MIM:609909]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:12610310, ECO:0000269|PubMed:16432188, ECO:0000269|PubMed:22137083, ECO:0000269|PubMed:22427649, ECO:0000269|PubMed:22707725}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In CMD1P; impairs phosphorylation by PKA and inhibition of ATP2A1-mediated calcium uptake.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  9
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  52
The length of the canonical sequence.

Location on the sequence:   MEKVQYLT  R SAIRRASTIEMPQQARQKLQ
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         MEKVQYLTRSAIRRASTIEMPQQARQKLQ

                              MDKVQYLTRSAIRRASTIEMPQQARQNLQ

Mouse                         MEKVQYLTRSAIRRASTIEMPQQARQNLQ

Rat                           MEKVQYLTRSAIRRASTIEMPQQARQNLQ

Pig                           MDKVQYLTRSAIRRASTIEMPQQARQNLQ

Bovine                        MDKVQYLTRSAIRRASTIEMPQQARQNLQ

Rabbit                        MEKVQYLTRSAIRRASTIEMPQQARQNLQ

Chicken                       MEKVQYITRSALRRASTLEVNPQARQRLQ

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 52 Cardiac phospholamban
Topological domain 1 – 31 Cytoplasmic
Modified residue 1 – 1 N-acetylmethionine
Modified residue 16 – 16 Phosphoserine; by PKA and DMPK
Modified residue 17 – 17 Phosphothreonine; by CaMK2
Mutagenesis 13 – 13 R -> A. Abolishes phosphorylation by PKA.
Mutagenesis 14 – 14 R -> A. Abolishes phosphorylation by PKA.
Mutagenesis 16 – 16 S -> A. Abolishes phosphorylation by PKA.
Mutagenesis 17 – 17 T -> A. No effect on phosphorylation by PKA.
Helix 4 – 14


Literature citations

Lethal, hereditary mutants of phospholamban elude phosphorylation by protein kinase A.
Ceholski D.K.; Trieber C.A.; Holmes C.F.; Young H.S.;
J. Biol. Chem. 287:26596-26605(2012)
Cited for: FUNCTION; CHARACTERIZATION OF VARIANTS CMD1P HIS-9; LEU-9; CYS-9 AND ARG-14 DEL; PHOSPHORYLATION AT SER-16; MUTAGENESIS OF ARG-13; ARG-14; SER-16 AND THR-17;

Mutations in the human phospholamban gene in patients with heart failure.
Medeiros A.; Biagi D.G.; Sobreira T.J.; de Oliveira P.S.; Negrao C.E.; Mansur A.J.; Krieger J.E.; Brum P.C.; Pereira A.C.;
Am. Heart J. 162:1088-1095(2011)
Cited for: VARIANTS CMD1P HIS-9 AND LEU-9;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.